Anzeige
Mehr »
Login
Montag, 20.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
52 Leser
Artikel bewerten:
(0)

Hands-On Treatment Improves Chronic Low Back Pain, Reduces Medication Use

FORT WORTH, Texas, March 18, 2013 /PRNewswire-USNewswire/ -- The numbers are staggering. More than 632 million people worldwide suffer from low back pain, and it is a leading cause of disability. According to the Institute of Medicine, one-third of all Americans suffer from chronic pain, which exceeds the number of people who are affected by heart disease, diabetes and cancer combined.

In the U.S., approximately 100 million adults are affected by chronic pain, and the economic costs ofMedical care and lost productivity total more than $550 billion annually.

"Chronic low back pain is an important component of these costs," said John Licciardone, D.O. and executive director of The Osteopathic Research Center at the UNT Health Science Center in Fort Worth (UNTHSC) and author of a study published today in the Annals of Family Medicine. "Our research offers hope in the form of a hands-on treatment that provides moderate to substantial improvement in pain, and that reduces the use of prescription medication."

This study, conducted at UNTHSC used osteopathic manual treatment (OMT) and ultrasound therapy to treat chronic low back pain in 455 adults. Patients in the study who received ultrasound therapy did not see any improvement, but the patients who received OMT saw significant improvement in pain, used less prescription medication and were more satisfied with their care over the 12 weeks of the study than those patients who did not receive OMT.

In study patients who received OMT, nearly two-thirds had a 30-percent reduction in their pain level, and half had a 50-percent reduction in their pain level. Patients received six treatments during the course of the study.

"One of the great benefits of OMT is that it has few side effects compared with other common treatments for low back pain that often involve serious side effects," Licciardone said. "In our study, patients who had higher levels of pain saw even greater reductions in pain. Not only does OMT reduce pain, it seems to work even better in people who experience higher pain levels. These are the people who are often treated with potentially addictive drugs such as OxyContin and Vicodin, epidural steroid injections or surgery.

If we can reduce the use of these drugs and invasive procedures by helping people to feel better with hands-on treatment that has few side effects, that is a plus for our patients and contributes to the management of chronic pain."

This research was funded by the National Institutes of Health-National Center for Complementary and Alternative Medicine (K24---AT002422) and the Osteopathic Heritage Foundation.

The UNT Health Science Center comprises the Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health, School of Health Professions and the UNT System College of Pharmacy (opening in fall 2013). Key research areas include aging and Alzheimer's disease, applied genetics, primary care and prevention.

In addition to its flagship school, the Texas College of Osteopathic Medicine, the UNT Health Science Center houses The Osteopathic Research Center, which is a leading research center in osteopathic medicine focusing on the effectiveness of OMT and other distinct aspects of osteopathic medical care.

SOURCE UNT Health Science Center

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.